Rallybio Corporation
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Stephen Uden
- Full Time Employees
- 15
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 234 Church Street New Haven CT United States of America 06510
- IPO Date
- Jul 29, 2021
- CIK
- 0001739410
- Website
- rallybio.com
- Similar Companies
- Business
- Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company founded in 2018 and headquartered at 234 Church Street in New Haven, Connecticut, develops transformative therapies for patients with severe rare diseases, focusing on areas of complement dysregulation and hematology; its lead product candidate, RLYB116, comprises a differentiated C5 inhibitor Affibody-ABD fusion protein in confirmatory pharmacokinetic/pharmacodynamic studies targeting immune platelet transfusion refractoriness and refractory antiphospholipid syndrome, while RLYB332 represents a preclinical long-acting matriptase-2 inhibitor monoclonal antibody for diseases of iron overload and severe anemias, RLYB114 includes a pegylated C5 inhibitor Affibody for ophthalmological complement dysregulation disorders, and the pipeline encompasses an undisclosed metabolic disease program. Rallybio operates primarily in the United States with global partnerships and targets patient populations underserved by current treatments in maternal-fetal health, immuno-inflammation, and metabolic disorders. In July 2025, the company sold its interest in the REV102 ENPP1 inhibitor program for hypophosphatasia—stemming from a prior joint venture with Recursion Pharmaceuticals—to Recursion for up to $25 million including a $7.5 million upfront equity payment, extending its cash runway into mid-2027 and sharpening focus on core pipeline assets; earlier in 2025, Rallybio discontinued development of RLYB212 following Phase 2 results in fetal and neonatal alloimmune thrombocytopenia prevention, while advancing natural history studies and planning key readouts for RLYB116.
Rallybio Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Rallybio Corporation - RLYB
Rallybio Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Rallybio Corporation - RLYB
Shareholder Alert: Ademi LLP investigates whether Rallybio Corporation is obtaining a Fair Price for Public Shareholders
Rallybio Corporation (RLYB) M&A Call Prepared Remarks Transcript
RLYB Stock Alert: Halper Sadeh LLC is Investigating Whether Rallybio Corporation is Obtaining a Fair Price for its Shareholders
RLYB Stock Alert: Halper Sadeh LLC is Investigating Whether Rallybio Corporation is Obtaining a Fair Price for its Shareholders
Rallybio Corporation and Avenzo Therapeutics Announce Merger Agreement to Advance Next-Generation Oncology Therapies and $215 Million Concurrent Private Placement
Are WSR, TERN, RLYB, DAWN Obtaining Fair Deals for their Shareholders?
Are EWCZ, STEL, RLYB, CTRA Obtaining Fair Deals for their Shareholders?
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger—EWCZ, STEL, RLYB, and CTRA
$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger—ALIS, TALK, JTAI, and RLYB
Are RLYB, VRME, AES Obtaining Fair Deals for their Shareholders?
Rallybio Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Rallybio Corporation - RLYB
Rallybio Corporation (RLYB) M&A Call Prepared Remarks Transcript
Tiny Biotech Rallybio Stock Surges As $500 Million-Backed Merger Fuels Investor Optimism
RLYB Stock Alert: Halper Sadeh LLC is Investigating Whether Rallybio Corporation is Obtaining a Fair Deal for its Shareholders
Rallybio Corporation and Candid Therapeutics Announce Merger Agreement
Rallybio Corporation and Candid Therapeutics Announce Merger Agreement
Short Interest in Rallybio Corporation (NASDAQ:RLYB) Declines By 72.5%
Rallybio Shares Successful Early-Stage Results for Rare Disease Drug; New Trial Set for Late 2026